Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 AML Highlights
24 January 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in acute myeloid leukemia (AML) from ASH 2023
The Post-ASH 2023 AML Highlights was supported by Genentech and Rigel. Supporters have no influence over the production of the content.
Session 1: Novel Therapies
Tuspetinib as monotherapy and combined with venetoclax
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Augment-101: revumenib monotherapy for R/R KMT2Ar acute leukemias
Ibrahim Aldoss City of Hope, Duarte, CA, United States
Panel discussion: novel therapies
Session 2: FLT3-Mutated Disease
DAC + VEN + Quiz for FLT3-ITDm AML
Musa Yilmaz University of Texas MD Anderson Cancer Center, Houston, TX, United States
PETHEMA QUIWI: FLT3-like gene expression signature predicts response to Quiz
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
BMT CTN 1506/MORPHO: FLT3-ITD VAF & survival are highly correlated
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Panel discussion: FLT3-mutated disease
Session 3: IDH-Mutated Disease
ASTX727: Comparison of AML regimens - a real-world evidence study
Himachandana Atluri The University of Texas MD Anderson Cancer Center, Houston, TX, United States
AML regimens in newly diagnosed patients with IDH1 mutations
Douglas Smith Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Panel discussion: IDH-mutated disease
Session 4: NPM1-Mutated Disease
CAVEAT study: venetoclax has potent efficacy in NPM1-mutated AML
Chong Chyn Chua Alfred Hospital and Monash University, Melbourne, Australia
Secondary-type mutations don't impact favorable outcome of NPM1m AML
Christoph Röllig University Hospital Carl Gustav Carus, Dresden, Germany
Influence of BM blast enumeration and co-occurring gene mutations
Curtis Lachowiez University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion: NPM1-mutated disease
Session 5: Transplantation
PTCy vs. conventional anti-GvHD prophylaxis
Arnon Nagler Chaim Sheba Medical Center, Tel Aviv, Israel
NCRI AML17 & AML19: allo-SCT in 1st complete remission in NPM1m AML
Jad Othman Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Panel discussion: transplantation
Session 6: Chemotherapy Combinations
SAL RELAX trial: HAM-VEN as salvage treatment for R/R AML
Christoph Röllig University Hospital Carl Gustav Carus, Dresden, Germany
NCRI AML18: MRD-directed treatment intensification in older AML patients
Nigel Russell Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
ASTX727 plus VEN for older and/or unfit patients with AML
Alexandre Bazinet MD Anderson Cancer Center, Houston, TX, United States
Pivekimab sunirine with AZA and VEN in patients with newly diagnosed AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion: chemotherapy combinations
Session 7: Stratification
Harmony: machine learning provides individualized prediction of outcomes
Alberto Hernández Sánchez Institute of Biomedical Research of Salamanca, Salamanca, Spain
Mutational & cytogenetic dynamics at diagnosis & relapse in AML
Alex Bataller MD Anderson Cancer Center, Houston, TX, United States
Single-cell characterization of TP53m AML
Hussein Abbas MD Anderson Cancer Center, Houston, TX, United States
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang University of Pennsylvania, Philadelphia, PA, United States
Panel discussion: stratification
Enduring Content from The Post-ASH 2023 AML Highlights has been supported by:
